Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00637494 · ClinicalTrials.gov registry record · Phase 3
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
A Phase 3 study, sponsored by Corcept Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT00637494 is a Phase 3 study that was terminated before completion, run by Corcept Therapeutics. The registered enrollment target is 292 participants.
The verdict
NCT00637494, a Phase 3 study, was terminated before completion, sponsored by Corcept Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.
Interventions
- DRUG placebo
- DRUG mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00637494
The ClinicalTrials.gov registry entry for NCT00637494 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00637494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00637494 about?
NCT00637494 is a clinical study titled "A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features". Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagno...
What is the current status of trial NCT00637494?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2008-03. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00637494?
The interventions under investigation include: placebo (DRUG), mifepristone (DRUG).
Who is sponsoring clinical trial NCT00637494?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.